HRS-4729 (KAI-4729) — Topline data
2027
Kailera remains on track to begin a Phase 1 trial in 2026 with data anticipated in 2027.Source filing
KLRA biotech catalysts & pipeline
KAILERA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
HRS-7535 (KAI-7535) — Topline data
2027
The trial initiated in April 2026, with data expected in 2027.Source filing
ribupatide injection (KAI-9531) — Topline data
H1 2027
• IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027Source filing
ribupatide injection (KAI-9531) — Topline data
mid-2027
Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027Source filing
ribupatide injection (KAI-9531) — Topline data
2028
Data are anticipated in 2028.Source filing
ribupatide injection (KAI-9531) — Conference presentation
Sep 28–Oct 2
Phase 1 ribupatide injection site trial data to be presented at the 2026 European Association for the Study of Diabetes Annual Meeting (EASD): The oral presentation titled "Effect of Injection Site on the Relative Bioavailability and Safety of Ribupatide, a Novel Dual GLP-1/GIP Receptor Agonist: Phase 1, Randomized, Single-Dose Crossover Study Results," will detail Kailera's Phase 1 injection site trial, which supported the ongoing global Phase 3 KaiNETIC clinical program.Source filing